Home/Pipeline/seRNA 003

seRNA 003

Glioblastoma

PreclinicalActive

Key Facts

Indication

Glioblastoma

Phase

Preclinical

Status

Active

Company

SRTD biotech

About SRTD biotech

SRTD Biotech is a private, preclinical-stage biotech developing a proprietary 'RNA pro-drug' platform termed seRNA (selectively expressed RNA). The technology merges RNA interference for cell-specific targeting with mRNA for effector molecule expression, delivered via proprietary lipid nanoparticles (fLNPs). The company's initial pipeline focuses on oncology (HCC, glioblastoma, lung cancer), with plans to expand into viral and autoimmune diseases, aiming to overcome the off-target side effects common to many existing therapies.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Viral Diseases

Other Glioblastoma Drugs

Drug	Company	Phase	Status
Ropidoxuridine (IPdR)	Shuttle Pharmaceuticals	Phase 2	Active
LNTH-2505	Lantheus Medical Imaging	Preclinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
Glioblastoma Moonshot	Owkin	Research	Open Project
OPC-001 (PDC Candidate)	Oncopeptides	Phase 1/Window-of-Opportunity	Active (Fast-Track Designation)
αvβ3-targeted ADC	Xintela	Preclinical	Lead Optimization
Undisclosed	Biossil	Phase 2/3	Active
GLIX1	Hemispherian	Phase 1	Active
InC01	InCephalo Therapeutics	Pre-clinical	Active
Glioblastoma Combination Therapy	JLP Health	Pre-clinical	Active
ENV105	Kairos Pharma	IND Cleared	Active
LMP744	Gibson Oncology	Phase 2	Active